Sai Parenterals Secures ₹104.5 Cr Contract For The Supply of Anti TB Products in Philippines Market

Synopsis: Sai Parenterals Limited has secured a long term international contract worth USD 11 million (around Rs. 104.5 crore) from Philippines based Pill Corp for the supply of anti tuberculosis products. The 10 year exclusive agreement strengthens the company’s export business and provides long term revenue visibility.

Pharmaceutical stock gained attention after securing a major international contract for the supply of anti tuberculosis products to the Philippines market. The latest development is expected to strengthen the company’s export order book and improve long term revenue visibility through recurring purchase orders.

Sai Parenterals Limited has a total market capitalization of Rs. 2,143 crore, according to data on the NSE. Sai Parenterals shares were trading at Rs. 486.10 apiece on the National Stock Exchange, up by 0.28 percent; the stock has declined around 1 percent over the last five sessions, while it has gone down about 0.17 percent in the 30 days. Over a six month period, the stock has given a positive return of 18.59 percent, whereas on a year on year basis it has surged nearly 75.40 percent, reflecting mixed overall performance. The stock’s 52 week high was Rs. 526.30 and 52 week low was Rs. 400. 

Sai Parenterals Limited has announced that it has received a purchase order valued at USD 11 million, equivalent to approximately Rs. 104.5 crore at an exchange rate of Rs. 95 per dollar, from Pill Corp, Bulacan, Philippines. The contract is for the supply of anti TB products on an exclusive basis for the Philippines market.

According to the company, the agreement will become effective from June 1, 2026 and will remain valid for a period of ten years. Purchase orders will be released periodically during the contract tenure, providing recurring business opportunities rather than a one time supply arrangement. The agreement may be revised, extended or terminated subject to contractual conditions and notice requirements.

The latest contract is strategically important for Sai Parenterals as it significantly strengthens the company’s international business portfolio and expands its presence in the anti tuberculosis therapeutics segment. Long term export contracts generally provide better revenue visibility, improve production planning and support capacity utilization for pharmaceutical manufacturers.

One of the key highlights of the agreement is its exclusivity structure. Under the arrangement, Sai Parenterals will serve as the exclusive supplier of the specified anti TB products for the Philippines market through Pill Corp. Such agreements can help establish long term customer relationships, reduce competitive pressures within the contract scope and improve business predictability over the contract period.

India continues to be one of the world’s largest suppliers of generic medicines and anti infective products. Rising healthcare spending, increasing focus on tuberculosis eradication programs and growing demand for affordable pharmaceutical formulations across emerging markets are expected to create long term growth opportunities for Indian pharmaceutical exporters.

A significant portion of growth for pharmaceutical companies increasingly comes from exports and international partnerships. The Philippines contract could help Sai Parenterals strengthen its overseas presence while diversifying revenue streams beyond the domestic market. However, investors should also note that export oriented businesses remain exposed to regulatory approvals, product registrations, currency fluctuations, pricing pressures and changes in healthcare procurement policies in international markets.

Incorporated in 2001, Sai Parenterals Limited is a diversified pharmaceutical formulations company with expertise in research, development and manufacturing. The company operates across multiple therapeutic categories and supplies pharmaceutical products to domestic and international markets.

Overall, the Rs. 104.5 crore international anti TB contract strengthens Sai Parenterals’ export order pipeline and supports long term business visibility. Going forward, execution of export orders, expansion into regulated markets, product diversification and additional international contracts will remain key factors influencing the company’s future performance.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Sai Parenterals Secures ₹104.5 Cr Contract For The Supply of Anti TB Products in Philippines Market appeared first on Trade Brains.